-$0.01 Earnings Per Share Expected for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) This Quarter

Brokerages expect Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) to post ($0.01) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Zomedica Pharmaceuticals Corp (NYSEAMERICAN)’s earnings. Zomedica Pharmaceuticals Corp (NYSEAMERICAN) reported earnings per share of ($0.02) in the same quarter last year, which would suggest a positive year-over-year growth rate of 50%. The firm is scheduled to announce its next quarterly earnings results on Thursday, August 13th.

According to Zacks, analysts expect that Zomedica Pharmaceuticals Corp (NYSEAMERICAN) will report full year earnings of ($0.04) per share for the current year. For the next year, analysts anticipate that the business will post earnings of ($0.03) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.02).

Several research firms have recently issued reports on ZOM. HC Wainwright restated a “buy” rating and set a $0.50 price objective (down previously from $0.65) on shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in a report on Wednesday, June 17th. Zacks Investment Research upgraded shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) from a “hold” rating to a “buy” rating and set a $0.25 price target on the stock in a report on Saturday, June 20th.

In other Zomedica Pharmaceuticals Corp (NYSEAMERICAN) news, Director Johnny D. Powers purchased 625,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The shares were bought at an average price of $0.16 per share, for a total transaction of $100,000.00. Following the acquisition, the director now owns 625,000 shares in the company, valued at $100,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 51.80% of the stock is currently owned by corporate insiders.

An institutional investor recently bought a new position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock. Clear Creek Financial Management LLC acquired a new position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 400,000 shares of the company’s stock, valued at approximately $95,000. Clear Creek Financial Management LLC owned approximately 0.37% of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) at the end of the most recent quarter. 11.77% of the stock is owned by institutional investors and hedge funds.

ZOM opened at $0.16 on Tuesday. Zomedica Pharmaceuticals Corp has a 52-week low of $0.11 and a 52-week high of $0.50. The firm’s 50-day moving average price is $0.19 and its 200-day moving average price is $0.20.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Company Profile

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.

See Also: How to invest in a bear market

Get a free copy of the Zacks research report on Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.